A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 15 May 2017
At a glance
- Drugs Amcasertib (Primary) ; Sorafenib
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 08 May 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 26 May 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Feb 2015 New trial record